111 related articles for article (PubMed ID: 21159902)
1. Hitting the target: new treatments for cystic fibrosis.
Davis SD; Ferkol TW
Am J Respir Crit Care Med; 2010 Dec; 182(12):1460-1. PubMed ID: 21159902
[No Abstract] [Full Text] [Related]
2. Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?
Tiddens HA; Donaldson SH; Rosenfeld M; Paré PD
Pediatr Pulmonol; 2010 Feb; 45(2):107-17. PubMed ID: 20082341
[TBL] [Abstract][Full Text] [Related]
3. Inhaled Mannitol (Bronchitol) for Cystic Fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Paediatr Respir Rev; 2016 Mar; 18():52-4. PubMed ID: 26867712
[No Abstract] [Full Text] [Related]
4. Exciting new clinical trials in cystic fibrosis: infants need not apply.
Stick SM; Sly PD
Am J Respir Crit Care Med; 2011 Jun; 183(12):1577-8. PubMed ID: 21693709
[No Abstract] [Full Text] [Related]
5. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis.
Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B;
Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203
[TBL] [Abstract][Full Text] [Related]
6. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
7. Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.
Moss RB
J Pediatr; 2013 Apr; 162(4):676-80. PubMed ID: 23290508
[No Abstract] [Full Text] [Related]
8. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial.
Teper A; Jaques A; Charlton B
J Cyst Fibros; 2011 Jan; 10(1):1-8. PubMed ID: 20888307
[TBL] [Abstract][Full Text] [Related]
9. Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
Ratjen F; Durham T; Navratil T; Schaberg A; Accurso FJ; Wainwright C; Barnes M; Moss RB;
J Cyst Fibros; 2012 Dec; 11(6):539-49. PubMed ID: 22682898
[TBL] [Abstract][Full Text] [Related]
10. Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis.
Goss CH; McKone EF; Mathews D; Kerr D; Wanger JS; Millard SP;
J Cyst Fibros; 2008 Mar; 7(2):147-53. PubMed ID: 17728193
[TBL] [Abstract][Full Text] [Related]
11. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.
Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW;
Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471
[TBL] [Abstract][Full Text] [Related]
12. [Non-cystic fibrosis bronchiectasis [corrected]].
Ringshausen FC; Rademacher J; Welte T
Dtsch Med Wochenschr; 2014 Apr; 139(14):707-10. PubMed ID: 24668431
[No Abstract] [Full Text] [Related]
13. Drug developers aim to treat cystic fibrosis through disease modification.
Thompson CA
Am J Health Syst Pharm; 2008 Dec; 65(24):2310-2. PubMed ID: 19052266
[No Abstract] [Full Text] [Related]
14. Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.
Kellerman D; Evans R; Mathews D; Shaffer C
Adv Drug Deliv Rev; 2002 Dec; 54(11):1463-74. PubMed ID: 12458155
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.
Deterding RR; Lavange LM; Engels JM; Mathews DW; Coquillette SJ; Brody AS; Millard SP; Ramsey BW;
Am J Respir Crit Care Med; 2007 Aug; 176(4):362-9. PubMed ID: 17446337
[TBL] [Abstract][Full Text] [Related]
16. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.
Kellerman D; Rossi Mospan A; Engels J; Schaberg A; Gorden J; Smiley L
Pulm Pharmacol Ther; 2008 Aug; 21(4):600-7. PubMed ID: 18276176
[TBL] [Abstract][Full Text] [Related]
17. Inhaled mannitol for the treatment of cystic fibrosis.
Hurt K; Bilton D
Expert Rev Respir Med; 2012 Feb; 6(1):19-26. PubMed ID: 22283575
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in cystic fibrosis.
Storey S; Wald G
Nat Rev Drug Discov; 2008 Jul; 7(7):555-6. PubMed ID: 18591977
[No Abstract] [Full Text] [Related]
19. Question 3: Inhaled mannitol improves lung function in patients with cystic fibrosis.
Winckworth LC; Holme H
Arch Dis Child; 2012 Nov; 97(11):1003-6. PubMed ID: 23100616
[No Abstract] [Full Text] [Related]
20. Cystic fibrosis papers of the year 2012.
Doull I
Paediatr Respir Rev; 2013 May; 14 Suppl 1():28-30. PubMed ID: 23452761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
